Iambic Therapeutics, Inc

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
HER2 (ErbB2), wild-type and oncogenic mutants including exon 20 insertionsSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
October 2028 (1)
IAM1363Phase 1/2HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors …
Est. primary completion 2028-10 · NCT06253871 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.